Molecular Targeted Therapy

"Molecular Targeted Therapy" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Treatments with drugs which interact with or block synthesis of specific cellular components characteristic of the individual's disease in order to stop or interrupt the specific biochemical dysfunction involved in progression of the disease.

Descriptor ID	D058990
MeSH Number(s)	E02.319.574
Concept/Terms	Molecular Targeted Therapy Molecular Targeted Therapy Molecular Targeted Therapies Targeted Therapies, Molecular Targeted Therapy, Molecular Therapies, Molecular Targeted Therapy, Molecular Targeted Targeted Molecular Therapy Molecular Therapies, Targeted Molecular Therapy, Targeted Targeted Molecular Therapies Therapies, Targeted Molecular Therapy, Targeted Molecular

Below are MeSH descriptors whose meaning is more general than "Molecular Targeted Therapy".

Analytical, Diagnostic and Therapeutic Techniques and Equipment [E]
Therapeutics [E02]
Drug Therapy [E02.319]
Molecular Targeted Therapy [E02.319.574]

Below are MeSH descriptors whose meaning is more specific than "Molecular Targeted Therapy".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Molecular Targeted Therapy" by people in this website by year, and whether "Molecular Targeted Therapy" was a major or minor topic of these publications.

Bar chart showing 104 publications over 12 distinct years, with a maximum of 19 publications in 2016

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2010	1	2	3
2011	0	5	5
2012	1	3	4
2013	1	3	4
2014	3	4	7
2015	4	13	17
2016	4	15	19
2017	4	8	12
2018	2	4	6
2019	4	9	13
2020	2	3	5
2021	2	7	9

Below are the most recent publications written about "Molecular Targeted Therapy" by people in Profiles.

Lei B, Sleiman MM, Cheng Q, Tu Z, Zhu P, Goddard M, Martins PN, Langerude L, Nadig S, Tomlinson S, Atkinson C. In Situ Pre-Treatment of Vascularized Composite Allografts With a Targeted Complement Inhibitor Protects Against Brain Death and Ischemia Reperfusion Induced Injuries. Front Immunol. 2021; 12:630581.

View in: PubMed
Lechner K, Mott S, Al-Saifi R, Knipfer L, Wirtz S, Atreya R, Vieth M, Rath T, Fraass T, Winter Z, August A, Luban J, Zimmermann VS, Weigmann B, Neurath MF. Targeting of the Tec Kinase ITK Drives Resolution of T Cell-Mediated Colitis and Emerges as Potential Therapeutic Option in Ulcerative Colitis. Gastroenterology. 2021 10; 161(4):1270-1287.e19.

View in: PubMed
Rizzo A, Mollica V, Santoni M, Rosellini M, Marchetti A, Ricci AD, Grilli G, Greco A, Montironi R, Ardizzoni A, Massari F. Comparative effectiveness of first-line immune checkpoint inhibitors plus tyrosine kinase inhibitors according to IMDC?risk groups in metastatic renal cell carcinoma: a meta-analysis. Immunotherapy. 2021 06; 13(9):783-793.

View in: PubMed
Lockbaum GJ, Henes M, Talledge N, Rusere LN, Kosovrasti K, Nalivaika EA, Somasundaran M, Ali A, Mansky LM, Kurt Yilmaz N, Schiffer CA. Inhibiting HTLV-1 Protease: A Viable Antiviral Target. ACS Chem Biol. 2021 03 19; 16(3):529-538.

View in: PubMed
Santoni M, Miccini F, Cimadamore A, Piva F, Massari F, Cheng L, Lopez-Beltran A, Montironi R, Battelli N. An update on investigational therapies that target STAT3 for the treatment of cancer. Expert Opin Investig Drugs. 2021 Mar; 30(3):245-251.

View in: PubMed
Rosellini M, Santoni M, Mollica V, Rizzo A, Cimadamore A, Scarpelli M, Storti N, Battelli N, Montironi R, Massari F. Treating Prostate Cancer by Antibody-Drug Conjugates. Int J Mol Sci. 2021 Feb 04; 22(4).

View in: PubMed
Roderick JE, Gallagher KM, Murphy LC, O'Connor KW, Tang K, Zhang B, Brehm MA, Greiner DL, Yu J, Zhu LJ, Green MR, Kelliher MA. Prostaglandin E2 stimulates cAMP signaling and resensitizes human leukemia cells to glucocorticoid-induced cell death. Blood. 2021 01 28; 137(4):500-512.

View in: PubMed
Johkoh T, Lee KS, Nishino M, Travis WD, Ryu JH, Lee HY, Ryerson CJ, Franquet T, Bankier AA, Brown KK, Goo JM, Kauczor HU, Lynch DA, Nicholson AG, Richeldi L, Schaefer-Prokop CM, Verschakelen J, Raoof S, Rubin GD, Powell C, Inoue Y, Hatabu H. Chest CT Diagnosis and Clinical Management of Drug-Related Pneumonitis in Patients Receiving Molecular Targeting Agents and Immune Checkpoint Inhibitors: A Position Paper From the Fleischner Society. Chest. 2021 03; 159(3):1107-1125.

View in: PubMed
Nayak S, Calvo JA, Cantor SB. Targeting translesion synthesis (TLS) to expose replication gaps, a unique cancer vulnerability. Expert Opin Ther Targets. 2021 01; 25(1):27-36.

View in: PubMed
Wang X, Sahu KK, Cerny J. Coagulopathy, endothelial dysfunction, thrombotic microangiopathy and complement activation: potential role of complement system inhibition in COVID-19. J Thromb Thrombolysis. 2021 Apr; 51(3):657-662.

View in: PubMed

People

Explore

Similar Concepts

Top Journals